Abstract: An improved foundation composition for application to the skin is disclosed. The composition is characterized by the inclusion of a light scattering agent having a spherical shape and a diameter of up to 30 microns. This component permits the non-inclusion of a colorant. The absence of a colorant allows the foundation composition to be invisible on the skin.

Abstract: An X-ray contrast composition comprising particles consisting essentially of a non-radioactive crystalline organic x-ray contrast agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than 400 nm, and a pharmaceutically acceptable carrier therefor is useful in x-ray diagnostic medical imaging methods. The agents can be delivered to a specific tissue or fluid site, for example, the blood pool, liver or spleen. In one embodiment involving intravenous administration, preferred compositions provide effective imaging of the blood pool for remarkably long times.

Abstract: A product and process for preparing a pharmaceutical composition for forming tablets, the composition containing pamabrom and pyrilamine maleate. In preferred embodiments, the composition also contains acetaminophen. A fluid bed granulator is charged with a first material containing pamabrom or pyrilamine maleate, and a first liquid containing pregelatinized starch is sprayed onto the first material so as to form a barrier coat. The barrier coated material is dried and then further coated with a second liquid containing only one of pamabrom and pyrilamine maleate, whichever was not present in the first material charged to the fluid bed granulator. The further coated material is then dried to a moisture content of from about 0.5% to less than about 2% by weight, so as to form particles in which the pamabrom and pyrilamine maleate are separated by the pregelatinized starch barrier.

Abstract: A medicinal salve composition and method for the topical treatment of a variety of deleterious skin conditions. The salve composition comprises a mixture of powdered sugar, boric acid, soybean oil, and a pharmaceutically-acceptable ointment base. The essential components of the present composition are combined in such relative proportionalities so as to form a homogeneous mixture having a consistency suitable for application to burns, wounds, lesions, and other skin traumas.

Abstract: This invention relates to compositions and methods for treating diseases of the oral cavity in humans and lower animals using a glycerol monooleate gel for releasing drugs in the oral cavity.

Abstract: Unit dosage form for delivering drugs into the body in a series of sequential, pulsatle releasing events employs conventional pharmaceutical equipment and processes for optimum economy, reliability, and bioavailability. The system can be used with drugs which cannot be released by diffusion through a porous coating, such as water insoluble drugs. A plurality of populations of pellets is provided within a unit dosage form such as a capsule or tablet. The pellets are composed of a core containing the drug and a swelling agent which expands in volume when exposed to water. The core is enclosed within a membrane or coating which is permeable to water. The membrane is composed of a water insoluble and permeable film forming polymer, a water soluble film forming polymer and a permeability reducing agent. When the unit dose releases the pellets into the digestive tract, water diffuses through the coating and into the core.

Abstract: A coating material for controlling drug release, useful for long acting formulations--e.g. for once-a-day administration, and to a long acting granular composition comprising a drug (especially one conventionally difficult to prepare in long acting form) coated with the coating material. This composition may be mixed with other granular drug formulations. The drug-release controlling coating material comprising, in a specific ratio, one specific water-insoluble and low water-permeability polymers and two materials differing from each other in the pH-dependency of their solubility (pH-dependent polymer-materials).

Abstract: A multi-dose insufflator for the nasal administration of medicaments in fine or micronized powder form comprises a reservoir unit (34), a unit (60, 64) for withdrawing and metering the medicament contained in the reservoir unit, and an insufflation unit (42, 26) comprising a manually operated pump (42) for generating an air stream within a channel (26) for conveying an individual dose of medicament into the nasal cavity of the patient. The withdrawal and metering unit comprises a conveyor device (60) provided with at least one cup (64) for withdrawing a dose of medicament from the reservoir (34) and conveying it into an insufflation position. The cup (64) has a coaxial base hole (66) through which the air stream generated by the pump passes when the cup is in the insufflation position. The hole (66) has a size substantially smaller than the mouth of the cup (64) and such as to prevent the powder medicament falling through the hole, by virtue of the "arching" effect.

Abstract: There is disclosed a process for the extraction of volatile solvents entrained in a polymer-based pharmaceutical composition designed for sustained release of drug over an extended period of time prepared in microcapsule form wherein the composition comprises at least one hormonally active water-soluble polypeptide in an effective amount greater than a conventional single dose and a biocompatible, bioerodable encapsulating polymer, which process comprises the steps of contacting the composition to a stream of dense gas, that is, pressurized gas and then removing the dense gas, and volatile solvents contained therein, extracted from the pharmaceutical composition.

Abstract: Delayed-release oral dosage forms are described comprising cimetidine or a salt thereof and optionally a buffer that is capable of aiding dissolution of cimetidine in the intestine, coated with a release-delaying substance comprising a coating agent such as Eudragit.RTM. L 30 D.

Abstract: Aerosol compositions for topical application, conferring a cooling effect on the body and suitable for use in the alleviation of pain, such as muscular or rheumatic pain, which compositions do not contain environmentally unacceptable chlorofluorocarbons but satisfy safety guidelines on flammability, and comprise an organic substance, other than a chlorofluorocarbon, having a boiling point within the range of from 10.degree. to 40.degree. C. and an organic substance, other than a chlorofluorocarbon, having a boiling point within the range of from -45.degree. to -10.degree. C., in a ratio of from 3 to 7 parts by weight of the higher boiling component (serving primarily as a coolant) per part by weight of the lower boiling component (serving primarily as a propellant).

Abstract: A substantially anhydrous composition suitable for topical application which contain 10-80% by weight of an anhydrous base which is liquid or semi-solid at room temperature; and 5-50% by weight of polyolefin microspherical particles having an average diameter of less than 25 microns, the amount of microspherical particles constituting at least 30% by weight of the anhydrous base.